{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:03:09Z","timestamp":1787238189519,"version":"build-2736575974"},"reference-count":181,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009822","name":"James G. Boswell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114263","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T02:17:22Z","timestamp":1722824242000},"page":"114263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Treating cancer-associated venous thromboembolism: A practical approach"],"prefix":"10.1016","volume":"209","author":[{"given":"Eric","family":"Van Cutsem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114263_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib2","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2024.114263_bib3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib4","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/COC.0b013e3181b01b17","article-title":"The link between cancer and venous thromboembolism: a review","volume":"32","author":"Kessler","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2024.114263_bib7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6605599","article-title":"Epidemiology and pathophysiology of cancer-associated thrombosis","volume":"102","author":"Noble","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","article-title":"Mechanisms and risk factors of thrombosis in cancer","volume":"118","author":"Falanga","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2024.114263_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2024.114263_bib11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib12","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejca.2024.114263_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"Sallah","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib16","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1538-7836.2004.01011.x","article-title":"Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway","volume":"2","author":"Miller","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2024.114263_bib18","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3390\/cancers12061354","article-title":"Incidence, therapy, and bleeding risk-cancer- associated thrombosis in patients with glioblastoma","volume":"12","author":"Muster","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114263_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11739-018-1956-1","article-title":"Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer","volume":"14","author":"Prisco","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejca.2024.114263_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ejca.2024.114263_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/17474086.2020.1751608","article-title":"Risk assessment of venous thromboembolism in hematological cancer patients: a review","volume":"13","author":"Chan","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ejca.2024.114263_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"Kekre","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.ejca.2024.114263_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40248-015-0021-4","article-title":"Venous thromboembolism and lung cancer: a review","volume":"10","author":"Vitale","year":"2015","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.ejca.2024.114263_bib24","article-title":"Risk factors and prognosis of pulmonary embolism in patients with lung cancer","volume":"96","author":"Ma","year":"2017","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejca.2024.114263_bib25","article-title":"Do lung cancer patients require routine anticoagulation treatment? A meta-analysis","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ejca.2024.114263_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3892\/etm.2022.11679","article-title":"Prevalence and treatment of venous thromboembolism in patients with solid tumors","volume":"24","author":"Zhao","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ejca.2024.114263_bib27","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/394740","article-title":"Arterial and venous thrombosis in cancer patients","volume":"2011","author":"Blann","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.ejca.2024.114263_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","article-title":"Cancer and the prothrombotic state","volume":"3","author":"Lip","year":"2002","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2024.114263_bib29","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"Moik","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib30","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib31","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","article-title":"Thrombotic events in patients with cancer receiving antiangiogenesis agents","volume":"27","author":"Zangari","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1358863X20914978","article-title":"Vascular effects of cancer treatments","volume":"25","author":"Campia","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.ejca.2024.114263_bib33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-13-284","article-title":"CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ejca.2024.114263_bib36","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib37","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib38","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats","volume":"26","author":"O'Connell","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114263_bib39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ejca.2024.114263_bib40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejca.2024.114263_bib41","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib42","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114263_bib43","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1160\/TH16-11-0840","article-title":"Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis","volume":"117","author":"Tafur","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib44","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2024.114263_bib45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/10781552211004705","article-title":"Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre","volume":"27","author":"Pelletier","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2024.114263_bib46","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114263_bib47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2024.114263_bib48","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2024.114263_bib49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood-2011-12-397752","article-title":"Multiple SNP testing improves risk prediction of first venous thrombosis","volume":"120","author":"de Haan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib50","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib52","first-page":"6S17","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient)","volume":"45","author":"Pernod","year":"2020","journal-title":"J Med Vasc"},{"key":"10.1016\/j.ejca.2024.114263_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1358863X15600256","article-title":"Direct oral anticoagulants (DOACs)","volume":"20","author":"Vazquez","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.ejca.2024.114263_bib54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2024.114263_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjcvp\/pvaa067","article-title":"Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials","volume":"7","author":"Elbadawi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejca.2024.114263_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib58","first-page":"95","article-title":"Edoxaban for cancer-associated venous thromboembolism","volume":"379","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib59","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib60","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib61","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004012","article-title":"Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study","volume":"19","author":"Khan","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2024.114263_bib63","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib64","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11239-019-01833-w","article-title":"Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study","volume":"47","author":"Woodruff","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ejca.2024.114263_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13338","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial","volume":"104","author":"McBane","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2024.114263_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib68","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: Rationale and design of the API-CAT study","volume":"122","author":"Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib69","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114263_bib71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2024.114263_bib72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2024.114263_bib73","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ejca.2024.114263_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib75","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.ejca.2024.114263_bib76","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib77","unstructured":"Cohen A., Keshishian A., Lee T., et al. Safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer: a retrospective analysis using four US claims databases (submitted to Am J Hematol)."},{"key":"10.1016\/j.ejca.2024.114263_bib78","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib79","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2024.114263_bib80","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2024.114263_bib81","first-page":"S193","article-title":"Abatacept monotherapy effectively reduces the frequency of osteoclast precursor cells in the peripheral blood of patients with rheumatoid arthritis and inhibits their differentiation into osteoclasts","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rhem"},{"key":"10.1016\/j.ejca.2024.114263_bib82","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.ejca.2024.114263_bib83","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib84","series-title":"StatPearls [Internet]","article-title":"Perioperative Anticoagulation Management","author":"Polania Gutierrez","year":"2023"},{"key":"10.1016\/j.ejca.2024.114263_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.accpm.2016.09.002","article-title":"Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) \u2013 September 2015","volume":"36","author":"Albaladejo","year":"2017","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.ejca.2024.114263_bib86","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1111\/jth.15896","article-title":"Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: guidance from the SSC of the ISTH","volume":"20","author":"Wang","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib87","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12959-021-00326-2","article-title":"The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines","volume":"19","author":"Alsubaie","year":"2021","journal-title":"Thromb J"},{"key":"10.1016\/j.ejca.2024.114263_bib88","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1517\/14656566.2015.1088003","article-title":"The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants","volume":"16","author":"Prandoni","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejca.2024.114263_bib89","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world- from the COMMAND VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.ejca.2024.114263_bib90","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease","volume":"20","author":"den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib91","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/cancers14081937","article-title":"In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients","volume":"14","author":"Po\u00e9nou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114263_bib92","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and prevention of cancer-associated thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114263_bib93","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib95","article-title":"A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","author":"Cohen","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib96","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib97","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.165.15.1782","article-title":"Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults","volume":"165","author":"White","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib99","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102190","article-title":"Treatment of venous thromboembolism in cancer patients: the dark side of the moon","volume":"96","author":"Becattini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.114263_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.acvd.2023.11.004","article-title":"Management of venous thromboembolic disease in patients with malignant brain tumours","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejca.2024.114263_bib102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.acvd.2023.11.009","article-title":"Management of cancer-associated thromboembolism in vulnerable population","volume":"117","author":"Laporte","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejca.2024.114263_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.acvd.2023.11.010","article-title":"Anticoagulant treatment of cancer-associated thromboembolism","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejca.2024.114263_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/hematology.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"2019","author":"Al-Samkari","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejca.2024.114263_bib105","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114263_bib106","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejca.2024.114263_bib107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/bloodadvances.2022009192","article-title":"DOACs in patients with brain cancers: promising but still a long way to go","volume":"7","author":"Giustozzi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114263_bib108","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.mayocp.2021.04.026","article-title":"Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism","volume":"96","author":"Houghton","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2024.114263_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12959-022-00399-7","article-title":"Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis","volume":"20","author":"Rungjirajittranon","year":"2022","journal-title":"Thromb J"},{"key":"10.1016\/j.ejca.2024.114263_bib110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2021-153442","article-title":"Safety of direct acting oral anticoagulants (DOACs) in comparison to low molecular weight heparin (LWMH) in gastrointestinal and genito-urinary cancers","volume":"138","author":"Rahman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib111","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib112","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.21037\/apm-21-658","article-title":"Role of direct oral anticoagulants in gastrointestinal cancer associated thrombosis \"practical issues in clinical practice\"-narrative review","volume":"10","author":"Jain","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2024.114263_bib113","unstructured":"Lang T., Vlazny D., Houghton D., Casanegra A., Meverden R., Froehling D., et al. Bleeding in patients with genitourinary cancer compared to non-genitourinary cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Res Pract Thromb Haemost. 2022:[abstract] OC 34.1."},{"key":"10.1016\/j.ejca.2024.114263_bib114","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio Study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.thromres.2020.06.025","article-title":"Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials","volume":"194","author":"Haykal","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib117","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2023.04.009","article-title":"Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer","volume":"226","author":"Cohen","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib118","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib119","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2024.114263_bib120","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/a-1777-4006","article-title":"Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors","volume":"122","author":"Lecumberri","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0039-3402806","article-title":"How I manage cancer-associated thrombosis","volume":"40","author":"Moik","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ejca.2024.114263_bib122","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.15748","article-title":"Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort","volume":"20","author":"Booth","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib123","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1182\/blood-2018-99-114204","volume":"132","author":"Boiles","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib124","article-title":"Inferior vena cava filters and complications: a systematic review","volume":"15","author":"Bajda","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2024.114263_bib125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.thromres.2017.03.012","article-title":"Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study","volume":"153","author":"Brunson","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib126","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2021-153442","article-title":"Safety of direct acting oral anticoagulants (DOACs) in comparison to low molecular weight heparin (LWMH) in gastrointestinal and genito-urinary cancers","volume":"138","author":"Rahman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib127","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jth.15215","article-title":"Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study","volume":"19","author":"Roopkumar","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib128","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221110171","article-title":"Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE\/NEJ037 study)","volume":"14","author":"Tsubata","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.114263_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib130","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.114263_bib131","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib132","article-title":"DOACs or VKAs or LMWH - What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis","volume":"79","author":"Yamani","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ejca.2024.114263_bib133","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2024.114263_bib134","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2024.114263_bib135","first-page":"6S31","article-title":"Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer","volume":"45","author":"Sebuhyan","year":"2020","journal-title":"J Med Vasc"},{"key":"10.1016\/j.ejca.2024.114263_bib136","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1007\/s00520-022-07235-8","article-title":"Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)","volume":"30","author":"Tsoukalas","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib137","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2017-0473","article-title":"Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting","volume":"23","author":"Riess","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114263_bib138","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/FJC.0000000000001142","article-title":"Direct acting oral anticoagulants following gastrointestinal tract surgery","volume":"78","author":"Hakeam","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejca.2024.114263_bib139","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ejca.2024.114263_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030662","article-title":"Absorption of direct oral anticoagulants in cancer patients after gastrectomy","volume":"14","author":"Puhr","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejca.2024.114263_bib141","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1007\/s00520-022-07135-x","article-title":"Treatment and secondary prophylaxis of venous thromboembolism in cancer patients","volume":"30","author":"Ali","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib142","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib144","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1002\/cam4.3118","article-title":"Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial","volume":"9","author":"Slagter","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114263_bib145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11239-018-1610-9","article-title":"Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism","volume":"45","author":"Kuperman","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ejca.2024.114263_bib146","doi-asserted-by":"crossref","first-page":"972.e1","DOI":"10.1016\/j.amjmed.2018.03.031","article-title":"Association of anemia with venous thromboembolism in acutely ill hospitalized patients: An APEX trial substudy","volume":"131","author":"Chi","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib147","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/jcph.1097","article-title":"Regional gastrointestinal absorption of apixaban in healthy subjects","volume":"58","author":"Byon","year":"2018","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.ejca.2024.114263_bib148","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib149","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib152","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/rth2.12492","article-title":"Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels","volume":"5","author":"Bravo Villa","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib153","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjmed.2023.01.010","article-title":"Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel","volume":"136","author":"Rosovsky","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2024.114263_bib154","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-07-0486","article-title":"Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro","volume":"101","author":"Jiang","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3174\/ajnr.A3000","article-title":"Dabigatran (Pradaxa)","volume":"33","author":"Comin","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ejca.2024.114263_bib156","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2024.114263_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2024.114263_bib161","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.chest.2019.12.040","article-title":"Morbid Obesity and Mortality in Patients With VTE: Findings From Real-Life Clinical Practice","volume":"157","author":"Giorgi-Pierfranceschi","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2024.114263_bib162","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.thromres.2014.01.021","article-title":"Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis","volume":"133","author":"Ikesaka","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib163","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0040-1715834","article-title":"Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study","volume":"121","author":"Martin","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib164","first-page":"356","article-title":"Olanzapine enhances the effect of conventional drugs in chemotherapy inducing nausea and vomiting: A randomized clinical trial","volume":"13","author":"Khani","year":"2022","journal-title":"Casp J Intern Med"},{"key":"10.1016\/j.ejca.2024.114263_bib165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The significance of drug\u2013drug and drug\u2013food interactions of oral anticoagulation","volume":"7","author":"Pascal Vranckx","year":"2017","journal-title":"Arrythmia Electrophysiol Rev"},{"key":"10.1016\/j.ejca.2024.114263_bib166","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jss.2016.06.089","article-title":"The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery","volume":"205","author":"Bellini","year":"2016","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2024.114263_bib167","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doz079","article-title":"The risk of venous thromboembolism after surgery for esophagogastric malignancy and the impact of chemotherapy: a population-based cohort study","volume":"33","author":"Adiamah","year":"2020","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ejca.2024.114263_bib168","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib169","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2021.279072","article-title":"Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial","volume":"107","author":"Becattini","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2024.114263_bib170","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11239-016-1386-8","article-title":"A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment","volume":"42","author":"Woodruff","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ejca.2024.114263_bib172","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2021.05.007","article-title":"The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE","volume":"203","author":"Goto","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib173","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejca.2024.114263_bib174","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/cancers12051144","article-title":"Direct oral anticoagulants in cancer patients. Time for a change in paradigm","volume":"12","author":"Wojtukiewicz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114263_bib175","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15785","article-title":"Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis","author":"Van der Linden","year":"2023","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.ejca.2024.114263_bib176","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620936325","article-title":"Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: A comprehensive review of interactions and mechanisms","volume":"26","author":"Peixoto de Miranda","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ejca.2024.114263_bib177","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2024.114263_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.1446","article-title":"Clinical Implications of Co-administering Apixaban With Key Interacting Medications","author":"Favatella","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ejca.2024.114263_bib179","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114263_bib180","article-title":"Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants","author":"Hellfritzsch","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ejca.2024.114263_bib182","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2024.114263_bib183","article-title":"How well do European patients understand cancer-associated thrombosis? A patient survey","volume":"31","author":"Falanga","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ejca.2024.114263_bib184","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2024.114263_bib185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0040-1714739","article-title":"Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)","volume":"121","author":"Picker","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib186","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.06.005","article-title":"Low-molecular-weight heparins for cancer-associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study","volume":"144","author":"Cajfinger","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2024.114263_bib187","first-page":"276","article-title":"Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - results from the CONKO-011 trial","volume":"44","author":"Sinn","year":"2021","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2024.114263_bib188","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejca.2024.114263_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.06.021","article-title":"Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study","volume":"206","author":"Cohen","year":"2021","journal-title":"Thromb Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:03:40Z","timestamp":1729868620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":181,"alternative-id":["S0959804924009195"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114263","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating cancer-associated venous thromboembolism: A practical approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114263"}}